Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma

BACKGROUND Recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) is generally an incurable disease, with patients experiencing median survival of under 10 months and significant morbidity. While immune checkpoint blockade (ICB) drugs are effective in approximately 20% of pa...

Full description

Bibliographic Details
Main Authors: Cristina Valero, Mahdi Golkaram, Joris L. Vos, Bin Xu, Conall Fitzgerald, Mark Lee, Shannon Kaplan, Catherine Y. Han, Xin Pei, Reith Sarkar, Lillian A. Boe, Abhinav Pandey, Elizabeth S. Koh, Charlotte L. Zuur, David B. Solit, Traci Pawlowski, Li Liu, Alan L. Ho, Diego Chowell, Nadeem Riaz, Timothy A. Chan, Luc G.T. Morris
Format: Article
Language:English
Published: American Society for Clinical Investigation 2023-10-01
Series:The Journal of Clinical Investigation
Subjects:
Immunology
Oncology
Online Access:https://doi.org/10.1172/JCI169823

Internet

https://doi.org/10.1172/JCI169823

Similar Items